Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526552 | 0.79 | PDPK1 (0.44) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL37384 | 0.79 | DPP4 (0.66) | DPP4XDHPDPK1GDAADORA3 | |
| Hydrochloric Acid SCHEMBL4763244 | 0.78 | DPP4 (0.63) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL11456967 | 0.78 | DPP4 (0.63) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL8719273 | 0.78 | DPP4 (0.63) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL2997392 | 0.76 | DPP4 (0.61) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL3002433 | 0.76 | DPP4 (0.61) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL11212991 | 0.76 | PDPK1 (0.41) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL2352414 | 0.76 | DPP4 (0.61) | DPP4XDHPDPK1GDAADORA3 | |
| SCHEMBL1551198 | 0.76 | DPP4 (0.61) | DPP4XDHPDPK1GDAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| CN-118422225-A | Preparation method of polysubstituted cyclic ether compound | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2024-08-02 | — | — | CN | claimed |
| CN-117467726-A | Preparation method of purine nucleoside | 天津凯莱英生物科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| CN-113939599-A | Hybrid all-LNA oligonucleotides | 豪夫迈·罗氏有限公司 | 2022-01-14 | — | — | CN | claimed |
| WO-2020245377-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-10 | — | — | WO | claimed |
| CN-108358927-A | 1,4- bis- replaces 1,2,3- ribavirin analogs and its preparation method and application | 郑州大学 | 2018-08-03 | — | — | CN | claimed |
| CN-105130989-B | A kind of 2 fluoroadenine synthetic methods | 新乡学院 | 2017-10-03 | — | — | CN | claimed |
| CN-102391356-B | Steroid n-glycoside analogue taking dihydro-pyranoid ring as D ring and preparation and application thereof | UNIV ZHENGZHOU | 2013-05-01 | — | — | CN | claimed |
| CN-102659785-A | 2-amino-6-aminomethylpurine compound and preparation method and application thereof | UNIV SHANDONG | 2012-09-12 | — | — | CN | claimed |
| CN-102391356-A | Steroid n-glycoside analogue taking dihydro-pyranoid ring as D ring and preparation and application thereof | UNIV ZHENGZHOU | 2012-03-28 | — | — | CN | claimed |
| US-20110269178-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2011-11-03 | — | — | US | claimed |
| EP-2330908-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | Georgetown University (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010019967-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | GEORGETOWN UNIVERSITY (US) | 2010-02-18 | — | — | WO | claimed |
| US-6369237-B1 | ENZYME INHIBITORS OF DNA GLYCOLASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-04-09 | — | — | US | claimed |
| WO-1998039334-A9 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | — | 1999-02-18 | — | — | WO | claimed |
| WO-1998039334-A1 | DNA GLYCOSYLASE INHIBITORS, AND USES RELATED THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1998-09-11 | — | — | WO | claimed |
| US-5118800-A | Oligonucleotides possessing a primary amino group in the terminal nucleotide | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1992-06-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269178-A1 | FLUORESCENT CDK INHIBITORS FOR TREATMENT OF CANCER | CDK3, CDK6, CDK8 | DPP4 2868/4885XDH 4313/4885PDPK1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.